Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis

European Journal of Medicinal Chemistry

Volumn 84, Issue , 2014, Pages 454-465

  Taha, Mutasem O ^a   Al Sha'Er, Mahmoud A ^b   Khanfar, Mohammad A ^a   Al Nadaf, Afaf H ^c  

^a UNIVERSITY OF JORDAN   (Jordan)

^b ZARQA UNIVERSITY   (Jordan)

^c APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

Author keywords

Anti inflammatory; Anticancer; Ligand based analysis; Phosphoinositide 3 kinase gamma; Serine peptidase

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN; LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; COMPLEX FORMATION; CRYSTALLOGRAPHY; GENETIC ALGORITHM; HYDROGEN BOND; HYDROPHILICITY; IC 50; IN VITRO STUDY; LIGAND BINDING; LIPOPHILICITY; NATIONAL HEALTH ORGANIZATION; PARTICLE SIZE; PHARMACOPHORE; PHYSICAL CHEMISTRY; PROTEIN PHOSPHORYLATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; VIRTUAL REALITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; IC50; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ALGORITHM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; HUMAN; METABOLISM; SYNTHESIS;

ALGORITHMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904888800     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.056     Document Type: Article

References (63)

1. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M.D. Waterfield Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer Annu. Rev. Cell Dev. Biol. 17 2001 615 675 (Pubitemid 33096187)
2. N.Y. Kalaany, and D.M. Sabatini Tumours with PI3K activation are resistant to dietary restriction Nature 458 2009 725 731
3. S. Ward, Y. Sotsios, J. Dowden, I. Bruce, and P. Finan Therapeutic potential of phosphoinositide 3-kinase inhibitors Chem. Biol. 10 2003 207 213 (Pubitemid 36380277)
4. S.G. Ward, and P. Finan Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents Curr. Opin. Pharmacol. 3 2003 426 434 (Pubitemid 36908947)
5. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M.D. Waterfield Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer Annu. Rev. Cell Dev. Biol. 17 2001 615 675 (Pubitemid 33096187)
6. 3CA gene in human cancers Science 304 2004 554 (Pubitemid 38541907)
7. N.R. Leslie, and C.P. Downes PTEN function: how normal cells control it and tumour cells lose it Biochem. J. 382 2004 1 11 (Pubitemid 39141560)
8. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, A.A. Sahin, K.S. Klos, P. Li, B.P. Monia, N.T. Nguyen, G.N. Hortobagyi, M.C. Hung, and D. Yu PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127 (Pubitemid 39485684)
9. Y. Xie, P.W. Abel, J.K. Kirui, C. Deng, P. Sharma, D.W. Wolff, M.L. Toews, and Y. Tu Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion Biochem. Pharmacol. 85 2013 1454 1462
10. F. Cappuzzo, E. Magrini, G.L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C.T. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato, and L. Crino Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J. Natl. Cancer Inst. 96 2004 1133 1141 (Pubitemid 39207049)
11. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167 (Pubitemid 39100331)
12. J. Luo, B.D. Manning, and L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 2003 257 262 (Pubitemid 37329790)
13. D.A. Sabbah, N.A. Simms, M.G. Brattain, J.L. Vennerstrom, and H. Zhong Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases J. Bioorg. Med. Chem. 22 2012 876 880
14. M.J. Zvelebil, M.D. Waterfield, and S.J. Shuttleworth Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors Arch. Biochem. Biophys. 477 2008 404 410
15. D.A. Sabbah, J.L. Vennerstrom, and H. Zhong Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases J. Chem. Inf. Model. 50 2010 1887 1898
16. Y. Oka, T. Yabuuchi, Y. Fujii, H. Ohtake, S. Wakahara, K. Matsumoto, M. Endo, Y. Tamura, and Y. Sekiguchi Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors Bioorg. Med. Chem. Lett. 22 2012 7534 7538
17. R.A. Beeley, and N.C. Sage GPCRs: an update on structural approaches to drug discovery Targets 2 2003 19 25
18. G. Klebe Virtual ligand screening: strategies, perspectives and limitations Drug Discov. Today 11 2006 580 594
19. H. Steuber, M. Zentgraf, C. Gerlach, C.A. Sotriffer, A. Heine, and G.J. Klebe Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions Mol. Biol. 363 2006 174 187 (Pubitemid 44414846)
20. M.T. Stubbs, S. Reyda, F. Dullweber, M. Moller, G. Klebe, D. Dorsch, W. Mederski, and H. Wurziger pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design Chem. Bio. Chem. 3 2002 246 249 (Pubitemid 36004503)
21. M.A. DePristo, P.I.W. de Bakker, and T.L. Blundell Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography Structure 12 2004 831 838 (Pubitemid 38595771)
22. M.O. Taha, Y. Bustanji, M.A.S. Al-Ghussein, M. Mohammad, H. Zalloum, I.M. Al-Masri, and N. Atallah Pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine and gemifloxacin J. Med. Chem. 51 2008 2062 2077 (Pubitemid 351503262)
23. M.O. Taha, N. Atallah, A.G. Al-Bakri, C. Paradis-Bleau, H. Zalloum, K. Younis, and R.C. Levesque Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening Bioorg. Med. Chem. 16 2008 1218 1235 (Pubitemid 351191777)
24. M.O. Taha, Y. Bustanji, A.G. Al-Bakri, M. Yousef, W.A. Zalloum, I.M. Al-Masri, and N. Atallah Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening J. Mol. Graph. Model. 25 2007 870 884 (Pubitemid 46216122)
25. I.M. Al-masri, M.K. Mohammad, and M.O. Taha Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening Chem. Med. Chem. 3 2008 1763 1779
26. M.O. Taha, L.A. Dahabiyeh, Y. Bustanji, H. Zalloum, and S. Saleh Combining ligand-based pharmacophore modeling, QSAR analysis and in-silico screening for the discovery of new potent hormone sensitive lipase inhibitors J. Med. Chem. 51 2008 6478 6494
27. A. Al-Nadaf, G. Abu Sheikha, and M.O. Taha Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads Bioorg. Med. Chem. 18 2010 3088 3115
28. A.M. Abu-Hammad, and M.O. Taha Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors J. Chem. Inf. Model. 49 2009 978 996
29. M.A. Al-Sha'er, S. VanPatten, Y. Al-Abed, and M.O. Taha Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors J. Mol. Graph. Model. 42 2013 104 114
30. M.A. Al-Sha'er, and M.O. Taha Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay Eur. J. Med. Chem. 45 2010 4316 4330
31. M.A. Al-Sha'er, and M.O. Taha Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors J. Chem. Inf. Model. 50 2010 1706 1723
32. M.A. Al-Sha'er, M.A. Khanfar, and M.O. Taha Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modelling and virtual screening followed by in vitro analysis J. Mol. Model. 20 2014 2080 2084
33. R.-R. Kuang, F. Qian, Z. Li, D.-Z. Wei, and Y. Tang Action mechanisms and structure-activity relationships of PI3Kγ inhibitors on the enzyme: a molecular modeling study Eur. J. Med. Chem. 41 2006 558 565
34. T.B. Lanni, K.L. Greene, C.N. Kolz, K.S. Para, M. Visnick, J.L. Mobley, D.T. Dudley, T.J. Baginski, and M.B. Liimatta Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinase Bioorg. Med. Chem. Lett. 17 2007 756 760 (Pubitemid 46108555)
35. V. Pomel, J. Klicic, D. Covini, D.D. Church, J.P. Shaw, K. Roulin, F. Burgat-Charvillon, D. Valognes, M. Camps, C. Chabert, C. Gillieron, B. Francüon, D. Perrin, D. Leroy, D. Gretener, A. Nichols, P.A. Vitte, S. Carboni, C. Rommel, M.K. Schwarz, and T. Rückle Furan-2-yl methylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-Kinase J. Med. Chem. 49 2006 3857 3871 (Pubitemid 43967883)
36. H. Li, J. Sutter, and R. Hoffmann O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design 2000 International University Line La Jolla, CA 173 189
37. R.P. Sheridan, and S.K. Kearsley Why do we need so many chemical similarity search methods? Drug Discov. Today 7 2002 903 911
38. J. Sutter, O. Güner, R. Hoffmann, H. Li, and M. Waldman O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design 2000 International University Line La Jolla. CA 501 511
39. Y. Kurogi, and O.F. Güner Pharmacophore modeling and three dimensional database searching for drug design using catalyst Curr. Med. Chem. 8 2001 1035 1055 (Pubitemid 32633658)
40. K. Poptodorov, T. Luu, T. Langer, and R. Hoffmann Methods and principles in medicinal chemistry R.D. Hoffmann, Pharmacophores and Pharmacophores Searches vol. 2 2006 Wiley-VCH Weinheim, Germany 17 47
41. CATALYST 4.11 Users' Manual 2005 Accelrys Software Inc. San Diego, CA
42. I.B. Bersuker, S. Bahçeci, and J.E. Boggs O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design 2000 International University Line La Jolla, CA 457 473
43. CERIUS2 LigandFit User Manual (Version 4.10) 2005 Accelrys Inc. San Diego, CA 3 48
44. R. Fischer The Principle of Experimentation Illustrated by a Psycho-physical Experiments eighth ed. 1966 Hafner Publishing Co. New York (Chapter II)
45. CERIUS2, QSAR Users' Manual, Version 4.10 2005 Accelrys Inc. San Diego, CA 43 88 221-235, 237-250
46. J. Kirchmair, P. Markt, S. Distinto, G. Wolber, and T. Langer Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection - what can we learn from earlier mistakes? J. Comput. Aided Mol. 22 2008 213 228 (Pubitemid 351447959)
47. T.R. Stouch, and P.C. Jurs A simple method for the representation, quantification, and comparison of the volumes and shapes of chemical compounds J. Chem. Inf. Comput. Sci. 26 1986 4 12
48. R.H. Rohrbaugh, and P.C. Jurs Molecular shape and prediction of high performance liquid chromatographic retention indices of polycyclic aromatic hydrocarbons Anal. Chem. 59 1987 1048
49. J.J. Irwin, and B.K. Shoichet ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Comput. Sci. 45 2005 177 182 (Pubitemid 40736970)
50. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, and H.-O. Bertrand Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4 J. Med. Chem. 48 2005 2534 2547 (Pubitemid 40520517)
51. L.F. Ramsey, and W.D. Schafer The Statistical Sleuth first ed. 1997 Wadsworth Publishing Company Belmont, CA
52. M.L. Verdonk, L. Marcel, V. Berdini, M.J. Hartshorn, W.T.M. Mooij, C.W. Murray, R.D. Taylor, and P. Watson Virtual screening using protein-ligand docking: avoiding artificial enrichment J. Chem. Inf. Comput. Sci. 44 2004 793 806
53. J.W. Leahy, C.A. Buhr, H.W. Johnson, B.G. Kim, T. Baik, J. Cannoy, T.P. Forsyth, J.W. Jeong, M.S. Lee, S. Ma, K. Noson, L. Wang, M. Williams, J.M. Nuss, E. Brooks, P. Foster, L. Goon, N. Heald, C. Holst, C. Jaeger, S. Lam, J. Lougheed, L. Nguyen, A. Plonowski, J. Song, T. Stout, X. Wu, M.F. Yakes, P. Yu, W. Zhang, P. Lamb, and O. Raeber Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors J. Med. Chem. 55 2012 5467 5482
54. O.O. Clement, and A.T. Mehl Pharmacophore perception, development, and use in drug design O.F. Guner, IUL Biotechnology Series 2000 International University Line La Jolla, CA 71 84
55. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623 (Pubitemid 34595232)
56. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26 (Pubitemid 33653411)
57. M.J. Fry Phosphoinositide (PI) 3-kinase assays Method Mol. Biol. 462 2008 1 18
58. E.H. Walker, M.E. Pacold, O. Perisic, L. Stephens, P.T. Hawkins, M.P. Wymann, and R.L. Williams Structural determinants of phosphoinositide 3-kinase inhibition by Wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 6 2000 909 919
59. M.O. Taha, M. Tarairah, H. Zalloum, and G. Abu-Sheikha Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits J. Mol. Graph. Model. 28 2010 383 400
60. A. Tropsha Beware of q2 J. Mol. Graph. Model. 20 2002 269 276
61. A. Tropsha Best practices for QSAR model development, validation, and exploitation Mol. Inf. 29 2010 476 488
62. M. Harder, B. Kuhn, and F. Diederich Efficient stacking on protein amide fragments ChemMedChem 8 2013 397 404
63. D.A. Sabbah, J.L. Vennerstrom, and H.A. Zhong Binding selectivity studies of phosphoinositide 3 gamma kinases using free energy calculations J. Chem. Inf. Model. 52 2012 3213 3224